These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31958097)

  • 1. Comparison of an Online-Only Parkinson's Disease Research Cohort to Cohorts Assessed In Person.
    Chahine LM; Chin I; Caspell-Garcia C; Standaert DG; Brown E; Smolensky L; Arnedo V; Daeschler D; Riley L; Korell M; Dobkin R; Amondikar N; Gradinscak S; Shoulson I; Dean M; Kwok K; Cannon P; Marek K; Kopil C; Tanner CM; Marras C;
    J Parkinsons Dis; 2020; 10(2):677-691. PubMed ID: 31958097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innovative Recruitment Strategies to Increase Diversity of Participation in Parkinson's Disease Research: The Fox Insight Cohort Experience.
    Dobkin RD; Amondikar N; Kopil C; Caspell-Garcia C; Brown E; Chahine LM; Marras C; Dahodwala N; Mantri S; Standaert DG; Dean M; Shoulson I; Marek K; Katz A; Korell M; Riley L; Tanner CM;
    J Parkinsons Dis; 2020; 10(2):665-675. PubMed ID: 32250321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
    Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
    Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study.
    Nalls MA; McLean CY; Rick J; Eberly S; Hutten SJ; Gwinn K; Sutherland M; Martinez M; Heutink P; Williams NM; Hardy J; Gasser T; Brice A; Price TR; Nicolas A; Keller MF; Molony C; Gibbs JR; Chen-Plotkin A; Suh E; Letson C; Fiandaca MS; Mapstone M; Federoff HJ; Noyce AJ; Morris H; Van Deerlin VM; Weintraub D; Zabetian C; Hernandez DG; Lesage S; Mullins M; Conley ED; Northover CA; Frasier M; Marek K; Day-Williams AG; Stone DJ; Ioannidis JP; Singleton AB;
    Lancet Neurol; 2015 Oct; 14(10):1002-9. PubMed ID: 26271532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and Relationship of Rest Tremor and Action Tremor in Parkinson's Disease.
    Gupta DK; Marano M; Zweber C; Boyd JT; Kuo SH
    Tremor Other Hyperkinet Mov (N Y); 2020 Dec; 10():58. PubMed ID: 33384882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.
    Latourelle JC; Beste MT; Hadzi TC; Miller RE; Oppenheim JN; Valko MP; Wuest DM; Church BW; Khalil IG; Hayete B; Venuto CS
    Lancet Neurol; 2017 Nov; 16(11):908-916. PubMed ID: 28958801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global, Yet Incomplete Overview of Cohort Studies in Parkinson's disease.
    Heinzel S; Lerche S; Maetzler W; Berg D
    J Parkinsons Dis; 2017; 7(3):423-432. PubMed ID: 28582871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of the COVID-19 Pandemic on People with Parkinson's Disease.
    Brown EG; Chahine LM; Goldman SM; Korell M; Mann E; Kinel DR; Arnedo V; Marek KL; Tanner CM
    J Parkinsons Dis; 2020; 10(4):1365-1377. PubMed ID: 32925107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood Neurofilament Light Chain in Parkinson's Disease: Comparability between Parkinson's Progression Markers Initiative (PPMI) and Asian Cohorts.
    Chen JH; Chan L; Chung CC; Bamodu OA; Hong CT
    J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
    Simuni T; Brumm MC; Uribe L; Caspell-Garcia C; Coffey CS; Siderowf A; Alcalay RN; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Nudelman K; Tosun-Turgut D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Bressman S; Marek K;
    Mov Disord; 2020 May; 35(5):833-844. PubMed ID: 32073681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.
    Healy DG; Falchi M; O'Sullivan SS; Bonifati V; Durr A; Bressman S; Brice A; Aasly J; Zabetian CP; Goldwurm S; Ferreira JJ; Tolosa E; Kay DM; Klein C; Williams DR; Marras C; Lang AE; Wszolek ZK; Berciano J; Schapira AH; Lynch T; Bhatia KP; Gasser T; Lees AJ; Wood NW;
    Lancet Neurol; 2008 Jul; 7(7):583-90. PubMed ID: 18539534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjusting for Underrepresentation Reveals Widespread Underestimation of Parkinson's Disease Symptom Burden.
    Hamedani AG; Auinger P; Willis AW; Safarpour D; Shprecher D; Stover N; Subramanian T; Cloud L
    Mov Disord; 2023 Sep; 38(9):1679-1687. PubMed ID: 37318322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of a virtual longitudinal observational study in Parkinson's disease (AT-HOME PD).
    Schneider RB; Omberg L; Macklin EA; Daeschler M; Bataille L; Anthwal S; Myers TL; Baloga E; Duquette S; Snyder P; Amodeo K; Tarolli CG; Adams JL; Callahan KF; Gottesman J; Kopil CM; Lungu C; Ascherio A; Beck JC; Biglan K; Espay AJ; Tanner C; Oakes D; Shoulson I; Novak D; Kayson E; Ray Dorsey E; Mangravite L; Schwarzschild MA; Simuni T;
    Ann Clin Transl Neurol; 2021 Feb; 8(2):308-320. PubMed ID: 33350601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study protocol of the DUtch PARkinson Cohort (DUPARC): a prospective, observational study of de novo Parkinson's disease patients for the identification and validation of biomarkers for Parkinson's disease subtypes, progression and pathophysiology.
    Boertien JM; van der Zee S; Chrysou A; Gerritsen MJJ; Jansonius NM; Spikman JM; van Laar T;
    BMC Neurol; 2020 Jun; 20(1):245. PubMed ID: 32534583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Parkinson's disease states and disease progression modelling: a longitudinal data study using machine learning.
    Severson KA; Chahine LM; Smolensky LA; Dhuliawala M; Frasier M; Ng K; Ghosh S; Hu J
    Lancet Digit Health; 2021 Sep; 3(9):e555-e564. PubMed ID: 34334334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort.
    Kang UJ; Goldman JG; Alcalay RN; Xie T; Tuite P; Henchcliffe C; Hogarth P; Amara AW; Frank S; Rudolph A; Casaceli C; Andrews H; Gwinn K; Sutherland M; Kopil C; Vincent L; Frasier M
    Mov Disord; 2016 Jun; 31(6):924-32. PubMed ID: 27113479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Video-based Parkinson's disease assessments in a nationwide cohort of Fox Insight participants.
    Myers TL; Tarolli CG; Adams JL; Barbano R; Cristina Gil-Díaz M; Spear KL; Lowell J; Daeschler M; Riley L; Amondikar N; Auinger P; Marras C; Tanner CM; Ray Dorsey E; Schneider RB
    Clin Park Relat Disord; 2021; 4():100094. PubMed ID: 34316671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program.
    Gwinn K; David KK; Swanson-Fischer C; Albin R; Hillaire-Clarke CS; Sieber BA; Lungu C; Bowman FD; Alcalay RN; Babcock D; Dawson TM; Dewey RB; Foroud T; German D; Huang X; Petyuk V; Potashkin JA; Saunders-Pullman R; Sutherland M; Walt DR; West AB; Zhang J; Chen-Plotkin A; Scherzer CR; Vaillancourt DE; Rosenthal LS
    Biomark Med; 2017 May; 11(6):451-473. PubMed ID: 28644039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson's disease patients.
    Swanson CR; Berlyand Y; Xie SX; Alcalay RN; Chahine LM; Chen-Plotkin AS
    Mov Disord; 2015 Oct; 30(12):1648-56. PubMed ID: 26207725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort.
    Simuni T; Caspell-Garcia C; Coffey CS; Weintraub D; Mollenhauer B; Lasch S; Tanner CM; Jennings D; Kieburtz K; Chahine LM; Marek K
    J Neurol Neurosurg Psychiatry; 2018 Jan; 89(1):78-88. PubMed ID: 28986467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.